Premium
Combination budesonide/formoterol inhaler as maintenance and reliever therapy in M āori with asthma
Author(s) -
Pilcher Janine,
Patel Mitesh,
Smith Ann,
Davies Cheryl,
Pritchard Alison,
Travers Justin,
Black Peter,
Weatherall Mark,
Beasley Richard,
Harwood Matire
Publication year - 2014
Publication title -
respirology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.857
H-Index - 85
eISSN - 1440-1843
pISSN - 1323-7799
DOI - 10.1111/resp.12319
Subject(s) - medicine , formoterol , budesonide/formoterol , inhaler , budesonide , regimen , asthma , randomized controlled trial , salbutamol , physical therapy
Background and objective There are significant health disparities between Māori and non‐Māori with asthma, a pattern seen between other ethnic populations. This study investigates outcomes for Māori in a randomized controlled trial ( RCT ) of combination budesonide/formoterol inhaler therapy in asthma. Methods This 24‐week multicentre RCT recruited 303 adult asthma patients, 44 of whom were M āori. Participants were randomized to the single combination budesonide/formoterol inhaler as maintenance and reliever therapy (‘ SMART ’) regimen or ‘standard’ regimen (combination budesonide/formoterol inhaler for maintenance and salbutamol as reliever). Outcomes included patterns of beta‐agonist inhaler use including ‘high use’ of reliever therapy (>8 actuations of budesonide/formoterol in excess of four maintenance doses per day for SMART and >16 actuations per day of salbutamol for standard). Differences in outcomes for Māori versus non‐Māori were assessed using an interaction term between ethnicity and treatment. Results With adjustment for ethnicity, the SMART group had fewer days of high use (relative rate ( RR ) 0.57 (95% confidence interval (CI): 0.38–0.85)), days of high use without medical review within 48 h ( RR 0.49 (95% CI: 0.32–0.75)) and severe exacerbations (RR 0.54 (95% CI: 0.36–0.81)) compared with standard. The magnitude of the benefit from the SMART regimen was similar in M āori and non‐ M āori. Regardless of treatment regimen, M āori demonstrated more days of high use, high use without medical review and underuse of maintenance therapy. Conclusions The SMART regimen has a favourable risk/benefit profile in M āori. Days of high use, days of high use without medical review and underuse of maintenance treatment were greater in Māori, regardless of treatment regimen.